Kevin Kunzmann

It becomes only the second FDA-approved drug for the movement disorder, following valbenazine (Ingrezza) earlier this year.

Surveyed LGB adults also reported notably greater rates of heart conditions with more lesbian and bisexual women reporting strokes and heart attacks than heterosexual women, and more gay and bisexual men reporting chest pain related to heart disease than heterosexual men.

GOCOVRI becomes the first drug ever approved for LID in Parkinson's disease patients.

The seizure-causing condition now inflicts at least 3.4 million US patients, according to the CDC.

Neurotoxin EB-001's fast treatment start-up and shorter duration could make for a different focal pain reliever.

The device provides hybrid pulsed radio frequency waveforms that create electromagnetic effects, offering immediate chronic intractable pain relief.

Hizentra prevents neuromuscular disability and impairment relapse in patients with CIDP, a rare immune-mediated disorder of the peripheral nerves.

The Better Care Reconciliation Act revision lost majority favor Monday night. On Tuesday night, majority leaders turned to a new plan.

Eluxadoline — a twice daily, oral medication used to treat adults with IBS-D — is a mu- and kappa-opioid receptor agonist and a delta-opioid receptor antagonist.

Two blood proteins have shown a combined 82% accuracy in diagnosing ASD in a group of pediatric patients.

Allen Bowling, MD, PhD, explains the benefits and roadblocks of alternative medicine for MS.

High-amylose maize starch with chemical add-ons prevented diabtes in susceptible mice in an Australian study.

The FDA accepted an abbreviated new drug application for Sandoz ANDA.

BMS-986168 significantly reduces CSF free eTau.

The study gauged elderly Parkinson's patients over a 5-year span.

Laxman Bahroo, DO, explains how no treatment has shown more efficacy for Tardive Dyskinesia against placebo than valbenazine (Ingrezza), and how its approval changes the scope of the movement disorder.

The ocular itching treatment is an ocular formulation of cetirizine.

He and a Danish team believe they've found the cause of multiple sclerosis.

The Mount Sinai Hospital neurology professor shares his thoughts on MS care.

The study presented at CMSC 2017 compared the treatments to an interferon.

Stephen Krieger, MD, an associate professor at Mount Sinai Hospital, discusses the impact that recently-approved drug ocrelizumab has on the state of multiple sclerosis care, as well as his patient-centered app that depicts the MS condition in a more accurate manner, at the 2017 Consortium of Multiple Sclerosis Centers in New Orleans.

Allen Bowling, MD, PhD, physician associate of the Colorado Neurological Institute, discussed widely-researched benefits of cannabis on MS effects, its shortcomings, and the broad outcomes of alternative treatment.

Clyde Markowitz, MD, director of the MS Center at the University of Pennsylvania, discusses how the patterns of male-to-female ratio in MS diagnoses may be linked to hormones, and whether testosterone could be key in bettering treatment.

Researcher calls it "some of the most exciting research in my career."